Compare · CMMB vs IVA
CMMB vs IVA
Side-by-side comparison of Chemomab Therapeutics Ltd. (CMMB) and Inventiva S.A. (IVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CMMB and IVA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- IVA is the larger of the two at $734.8M, about 78.6x CMMB ($9.3M).
- Over the past year, CMMB is down 61.9% and IVA is down 39.0% - IVA leads by 22.8 points.
- IVA has been more active in the news (4 items in the past 4 weeks vs 1 for CMMB).
- IVA has more recent analyst coverage (17 ratings vs 5 for CMMB).
- Company
- Chemomab Therapeutics Ltd.
- Inventiva S.A.
- Price
- $1.26-2.70%
- $2.95-4.99%
- Market cap
- $9.3M
- $734.8M
- 1M return
- -52.81%
- -21.33%
- 1Y return
- -61.88%
- -39.05%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 1
- 4
- Recent ratings
- 5
- 17
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Latest CMMB
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Amendment: SEC Form SCHEDULE 13D/A filed by Chemomab Therapeutics Ltd.
- Director Cohen Neil Harris sold $6,516 worth of American Depositary Shares (2,304 units at $2.83), decreasing direct ownership by 7% to 33,000 units (SEC Form 4)
- Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13D filed by Chemomab Therapeutics Ltd.
- Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- SEC Form 3 filed by new insider Melincoff Gwen A
Latest IVA
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
- Inventiva to Present Multiple Abstracts at Paris MASH 2026
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
- SEC Form 6-K filed by Inventiva S.A.
- Inventiva Appoints Chris Benecchi as Chief Operating Officer
- Amendment: SEC Form 6-K/A filed by Inventiva S.A.